Thursday, April 24, 2014

Juno Therapeutics Raises $176M

Seattle-based Juno Therapeutics announced this morning that it has raised $176M in a series A funding round, for its cancer immunotherapy efforts. According to the company, the funding came primarily from ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors. It other investors include Bezos Expeditions and Venrock, among others. Juno is developing immunotherapies for cancer, and is led by Hans Bishop. More information »